These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24130356)

  • 1. Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial.
    van Golen LW; IJzerman RG; Huisman MC; Hensbergen JF; Hoogma RP; Drent ML; Lammertsma AA; Diamant M
    Diabetes Care; 2013 Dec; 36(12):4050-6. PubMed ID: 24130356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial.
    van Golen LW; Veltman DJ; IJzerman RG; Deijen JB; Heijboer AC; Barkhof F; Drent ML; Diamant M
    PLoS One; 2014; 9(4):e94483. PubMed ID: 24739875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
    Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
    Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
    Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC; Bogoev M; Larsen J; Philotheou A
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
    Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
    Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM
    Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.
    Zachariah S; Sheldon B; Shojaee-Moradie F; Jackson NC; Backhouse K; Johnsen S; Jones RH; Umpleby AM; Russell-Jones DL
    Diabetes Care; 2011 Jul; 34(7):1487-91. PubMed ID: 21593292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I; Vague P; Selam JL; Skeie S; Lang H; Draeger E; Elte JW
    Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
    Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
    Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
    Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes.
    Herring R; Knight R; Shojaee-Moradie F; Johnsen S; Umpleby AM; Jackson N; Jones R; Dijk DJ; Russell-Jones DL
    Diabetes Obes Metab; 2015 Nov; 17(11):1100-3. PubMed ID: 26272173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients.
    Hendriksen KV; Jensen T; Oturai P; Feldt-Rasmussen B
    Diabetologia; 2012 Jan; 55(1):46-50. PubMed ID: 22002075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.